Revenue
2022
2023
2024
2025
60 DEGREES PHARMACEUTICALS, INC. (SXTP)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.0M | $607,574 | $253,573 | $223,208 |
| Gross profit | $223,776 | $222,809 | −$220,977 | −$209,162 |
| Research & development | $2.1M | $5.0M | $691,770 | $525,563 |
| Operating expenses | $8.4M | $10.0M | $4.9M | $1.8M |
| Operating income | −$7.8M | −$9.7M | −$5.2M | −$1.8M |
| EBITDAderived | −$7.7M | −$9.7M | −$5.1M | −$1.7M |
| Net income | −$7.4M | −$7.9M | −$3.8M | −$6.2M |
| Basic EPSper diluted share | -$11.73 | -$74.17 | -$59.18 | -$2.61 |
| Diluted EPSper diluted share | -$11.73 | -$74.17 | -$59.18 | -$2.61 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 | DOW GEOFFREY SPresident and CEO | BuyCommon Stock | 7.3K | $1.38 | $10.1K | 24.1K |
| Dec 15, 2025Form 4 | DOW GEOFFREY SPresident and CEO | BuyCommon Stock | 9.7K | $0.80 | $7.7K | 59.6K |
| Dec 11, 2025Form 4 | DOW GEOFFREY SPresident and CEO | BuyCommon Stock | 3.6K | $0.92 | $3.3K | 49.9K |
| Dec 10, 2025Form 4 | DOW GEOFFREY SPresident and CEO | BuyCommon Stock | 9.3K | $0.95 | $8.9K | 46.3K |
| Jun 3, 2025Form 4 | XU CHERYLDirector | BuyCommon Stock | 2.0K | $2.90 | $5.8K | 15.8K |